IFNA1 and systemic sclerosis: Although the specific role of type I IFN in SSc epidermis is unknown, our data show that keratinocytes respond to the enriched IFN environment in SSc skin (51) and are sensitive markers of suppression of IFN signaling with tofacitinib.